Bianco, a longtime worst biotech CEO nominee, broke through this year and finally shoved his way into loser's circle by managing to engineer a 77% drop in his company's price despite finally winning European approval for the its lymphoma drug.
See if (BPAX) is in our portfolio
In many ways, TheStreet's biotechnology readers are (dis)honoring Bianco for a lifetime of investor bamboozlement and self-enrichment. The numbers that define Bianco's career as chief executive of Cell Therapeutics are stunning: Total losses of more than $1.7 billion, a 99.99999999% drop in the value of company shares and total compensation for him and his hand-picked team of executive cronies in the tens of millions of dollars.
Bianco wins this year's Worst Biotech CEO Award with 37% of the record-breaking 30,239 total votes cast.
3 dol is nothing many other in phase 2 only hit 10 dol or more ctic has a portfolio of 4 major products in phase and should close next week in the 4 dol range and should be eventually purchased in the 15 dol range imminently
those who are talking negativity are those who are buying .......
News 
Market Data 
Discover 
AI
